Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

INSM

Insmed Inc

Sep 12 • 04:00PM ET

145.93

+0.14 0.10 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BIIB REGN GILD RARE NBIX UTHR SRPT EXEL BMRN

| Held by: VTI VB VBK VXF IBB XBI IWP IWR IWF JGRO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.70	Insider Own	1.97%	Shs Outstand	211.11M	Perf Week	0.57%
Market Cap	30.85B	Forward P/E	-	EPS next Y	-3.79	Insider Trans	-20.35%	Shs Float	207.22M	Perf Month	18.77%
Enterprise Value	29.73B	PEG	-	EPS next Q	-1.33	Inst Own	99.33%	Short Float	5.10%	Perf Quarter	50.63%
Income	-1034.34M	P/S	77.48	EPS this Y	0.94%	Inst Trans	5.95%	Short Ratio	3.05	Perf Half Y	94.39%
Sales	398.11M	P/B	24.65	EPS next Y	31.37%	ROA	-48.22%	Short Interest	10.56M	Perf YTD	111.37%
Book/sh	5.92	P/C	16.61	EPS next 5Y	50.45%	ROE	-160.54%	52W High	149.08 -2.11%	Perf Year	103.90%
Cash/sh	8.78	P/FCF	-	EPS past 3/5Y	-12.84% -13.12%	ROIC	-52.18%	52W Low	60.40 141.61%	Perf 3Y	488.19%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	24.50% 21.66%	Gross Margin	74.45%	Volatility	2.42% 2.73%	Perf 5Y	431.62%
Dividend TTM	-	EV/Sales	74.69	EPS Y/Y TTM	-5.65%	Oper. Margin	-233.02%	ATR (14)	3.89	Perf 10Y	481.16%
Dividend Ex-Date	-	Quick Ratio	6.33	Sales Y/Y TTM	21.15%	Profit Margin	-259.82%	RSI (14)	77.34	Recom	1.15
Dividend Gr. 3/5Y	- -	Current Ratio	6.68	EPS Q/Q	12.55%	SMA20	6.12%	Beta	1.03	Target Price	156.24
Payout	-	Debt/Eq	0.59	Sales Q/Q	18.90%	SMA50	23.01%	Rel Volume	0.56	Prev Close	145.79
Employees	1271	LT Debt/Eq	0.59	Earnings	Aug 07 BMO	SMA200	68.29%	Avg Volume	3.46M	Price	145.93
IPO	Feb 15, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	-31.51% 3.16%	Trades		Volume	1,925,973	Change	0.10%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-25	Initiated	William Blair	Outperform
Aug-13-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$126
May-13-25	Initiated	Jefferies	Buy	$105
Feb-25-25	Initiated	RBC Capital Mkts	Outperform	$100
Apr-23-24	Initiated	Truist	Buy	$48
Feb-15-24	Initiated	Wolfe Research	Outperform	$42
Dec-08-23	Initiated	Wells Fargo	Overweight	$55
Nov-20-23	Resumed	JP Morgan	Overweight	$36
Jul-26-23	Initiated	Guggenheim	Buy	$50
Dec-09-22	Initiated	Mizuho	Buy	$28
Dec-07-22	Initiated	Barclays	Overweight	$37
Nov-18-22	Initiated	BofA Securities	Buy	$39
Apr-27-22	Initiated	Goldman	Buy	$56
Dec-06-21	Initiated	JP Morgan	Overweight	$45
Oct-19-21	Resumed	Morgan Stanley	Overweight	$56 → $52
Oct-19-21	Resumed	Monness Crespi & Hardt	Buy	$52
Oct-08-21	Initiated	Cantor Fitzgerald	Overweight	$60
Apr-26-21	Resumed	Credit Suisse	Outperform	$60
Dec-17-20	Initiated	Berenberg	Buy	$48
Oct-12-20	Resumed	Stifel	Buy	$44

Show Previous Ratings

Sep-12-25 08:09AM	Insmed (INSM) Reported Impressive Results from the Phase 2 Trial Of Its Inhalation Powder (Insider Monkey)
Sep-05-25 05:11PM	Top Analyst Reports for Microsoft, Amazon.com & Philip Morris (Zacks)
07:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-04-25 09:42AM	Insmed scores pivotal win in bronchiectasis with FDA approval of Brinsupri (Pharmaceutical Technology)
Sep-03-25 01:48PM	UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals (Zacks)
04:09PM	Loading…
Sep-02-25 04:09PM	Why United Therapeutics Catapulted 33%, Pulling Insmed, Liquidia With It (Investor's Business Daily) +6.76%
09:34AM	Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It (Investor's Business Daily)
01:04AM	What Does Wall Street Think About Insmed Incorporated (INSM)? (Insider Monkey)
Aug-27-25 04:32PM	Bloomberg 500 (B500) Index Adds Sixteen Securities Following Semi-Annual Reconstitution (PR Newswire)
Aug-22-25 05:11AM	Magazine: Big biopharma take on the ADC challenge (Pharmaceutical Technology)
Aug-21-25 07:00AM	Insmed To Present at September Investor Conferences (PR Newswire)
Aug-19-25 01:21PM	Josh Brown's Best Stocks in the Market: Insmed (CNBC TV)
10:15AM	This Strong Buy Pharma Stock Is Surging to New Highs (Barchart)
Aug-14-25 02:05PM	Mizuho's Jared Holz on how to play the underperforming health care sector (CNBC TV)
09:45AM	C3 AI downgraded, Capri upgraded: Wall Streets top analyst calls (TipRanks)
06:56PM	Loading…
Aug-13-25 06:56PM	Insmed CEO on what's next for company after FDA greenlights lung disease drug (CNBC TV)
12:31PM	VytlOne Announces New Partnership with Insmed (PR Newswire)
09:40AM	C3 AI downgraded, Capri upgraded: Wall Street's top analyst calls (The Fly)
08:30AM	PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis (PR Newswire)
07:56AM	Insmed wins FDA approval for future blockbuster Brinsupri (Pharmaceutical Technology)
Aug-12-25 04:30PM	Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval (Investor's Business Daily) +8.07%
02:20PM	FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease (Benzinga)
01:04PM	Insmed gains US approval of lung disease drug forecast to be blockbuster (BioPharma Dive)
11:34AM	FDA Approves BRINSUPRI (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease (PR Newswire)
Aug-11-25 09:15AM	Don't Overlook Insmed (INSM) International Revenue Trends While Assessing the Stock (Zacks)
Aug-07-25 09:30AM	Insmed (INSM) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:20AM	Insmed (INSM) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:17AM	Insmed: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
Aug-06-25 07:45AM	Fortrea Holdings Inc. (FTRE) Beats Q2 Earnings and Revenue Estimates (Zacks)
07:00AM	Loading…
07:00AM	OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee (GlobeNewswire)
Aug-05-25 09:15AM	Insmed (INSM) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates (Zacks)
Aug-04-25 08:30AM	Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas (PR Newswire)
Jul-31-25 12:35PM	Insmed's Pipeline Growth With Brensocatib Approval And Phase 3 Trials (Insider Monkey)
10:00AM	Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know (Zacks)
08:00AM	Strong Drug Development Momentum Lifted Insmed Incorporated (INSM) in Q2 (Insider Monkey)
Jul-30-25 12:37PM	Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains. (Barrons.com)
Jul-28-25 03:00AM	Synthetic rescue: Insmed explores a new frontier in genetic therapeutics (Pharmaceutical Technology)
Jul-25-25 11:28PM	Wells Fargo Lifts PT on Insmed Incorporated (INSM) to $130 From $119, Keeps a Buy Rating (Insider Monkey)
Jul-24-25 08:00AM	Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work? (Investor's Business Daily)
07:00AM	Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025 (PR Newswire)
Jul-17-25 11:11AM	Nontuberculous Mycobacteria (NTM) Opportunity Assessment and Forecast to 2033 Featuring Janssen, Novartis, Meiji Seika Pharma, Insmed, Daiichi Sankyo, MannKind, Paratek, Nobelpharma, GSK, Pfizer (GlobeNewswire)
06:20AM	Should iShares Russell 2000 ETF (IWM) Be on Your Investing Radar? (Zacks)
Jul-14-25 02:46PM	Jim Cramer Calls Insmed "Very Speculative" (Insider Monkey)
Jul-09-25 08:55PM	Lightning Round: When it comes to AI, I believe in Nvidia, says Jim Cramer (CNBC TV)
Jun-20-25 07:08AM	Russell Rebalance: 3 Stocks Ready to Move Higher (MarketBeat)
Jun-17-25 11:23AM	Wells Fargo Lifts Price Target on Insmed Incorporated (INSM) to $119 From $107 (Insider Monkey)
Jun-13-25 02:10PM	Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results (Insider Monkey)
06:00AM	AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans (BioPharma Dive)
Jun-12-25 06:37PM	Insmed (INSM) Soars After Raising $650 million (Insider Monkey)
06:32PM	Insmed Inc (INSM) Soars 30% on Impressive Study (Insider Monkey)
Jun-11-25 10:25PM	Insmed Announces Pricing of $750 Million Public Offering of Common Stock (PR Newswire) +7.75%
07:40PM	Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM) (Insider Monkey)
04:01PM	Insmed Announces Proposed $650 Million Public Offering of Common Stock (PR Newswire)
01:32PM	Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast (Benzinga)
11:04AM	Insmed Stock Jumps 29% on Encouraging PAH Study Results (Zacks)
06:20AM	Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar? (Zacks)
05:57AM	Insmed surges on lung drug data; Recursion cuts staff (BioPharma Dive)
Jun-10-25 06:08PM	Insmed CEO Will Lewis on stock surge after positive trial results (CNBC TV) +28.65%
04:07PM	Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia (Investor's Business Daily)
02:48PM	Insmed Stock Soars on Pulmonary Arterial Hypertension Drug Trial Results (Investopedia)
01:07PM	OpenAI-Google cloud deal, metals rally, Insmed trial results (Yahoo Finance Video)
11:32AM	TSMC revenue jump, Insmed stock skyrockets: Trending Tickers (Yahoo Finance Video)
11:29AM	Insmed Stock Jumps 28% on Experimental Hypertension Drug Trial Results (Barrons.com)
09:52AM	Insmed Stock Skyrockets Following Experimental Drug Trial Results (Barrons.com)
07:00AM	Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension (PR Newswire)
Jun-06-25 06:20AM	Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar? (Zacks)
06:20AM	Should Vanguard Russell 2000 ETF (VTWO) Be on Your Investing Radar? (Zacks)
Jun-04-25 04:05PM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
May-29-25 06:20AM	Should Global X Russell 2000 ETF (RSSL) Be on Your Investing Radar? (Zacks)
May-28-25 07:10AM	Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference (PR Newswire)
May-21-25 04:05PM	Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study (PR Newswire)
May-15-25 06:20AM	Should iShares Russell 2000 ETF (IWM) Be on Your Investing Radar? (Zacks)
May-14-25 07:39AM	Insmed Incorporated (INSM): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying (Insider Monkey)
May-13-25 09:16AM	Unlocking Insmed (INSM) International Revenues: Trends, Surprises, and Prospects (Zacks)
May-09-25 12:41PM	Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates (Zacks)
10:21AM	Is Insmed Incorporated (INSM) One of the Best Cancer Stocks to Invest in for Long-Term Gain? (Insider Monkey)
May-08-25 08:15AM	Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:13AM	Insmed: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
12:11PM	Insmed Q1 2025 Earnings Preview (Seeking Alpha)
May-06-25 06:20AM	Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now? (Zacks) -6.49%
May-04-25 11:38AM	Insmed Incorporated (INSM): Among the Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy (Insider Monkey)
May-01-25 11:35AM	ClearBridge Small Cap Growth Fund Q1 2025 Commentary (Seeking Alpha)
10:01AM	Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline (Zacks)
Apr-30-25 02:34PM	Insmed Incorporated (INSM): Among Billionaire George Soros' Mid-Cap Stocks With Huge Upside Potential (Insider Monkey)
Apr-29-25 09:30PM	Franklin Convertible Securities Fund Q1 2025 Commentary (Seeking Alpha)
11:30AM	Baron Health Care Fund Q1 2025 Top Contributors And Detractors (Seeking Alpha)
07:00AM	Insmed To Present at the BofA Securities 2025 Health Care Conference (PR Newswire)
Apr-27-25 02:22PM	Baron Health Care Fund Q1 2025 Shareholder Letter (Seeking Alpha)
Apr-25-25 11:58AM	Insmed: Poised For Transformation Beyond ARIKAYCE (Seeking Alpha)
Apr-24-25 02:50PM	TimesSquare U.S. Mid Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
07:00AM	Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028 (PR Newswire)
Apr-23-25 08:46PM	Insmed Incorporated (INSM): Among Takeover Rumors Hedge Funds Are Buying (Insider Monkey)
05:00PM	New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis (PR Newswire)
02:58PM	TimesSquare U.S. Small Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
07:00AM	Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025 (PR Newswire)
Apr-22-25 03:27AM	Polaris Global Equity Composite Q1 2025 Commentary (Seeking Alpha)
Apr-21-25 06:20AM	Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar? (Zacks)

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schaeffer Orlov S Nicole	Officer	Sep 12 '25	Proposed Sale	145.42	76,520	11,127,662		Sep 12 05:03 PM
SHAROKY MELVIN MD	Director	Sep 12 '25	Proposed Sale	145.00	10,000	1,450,000		Sep 12 03:55 PM
Smith Michael Alexander	Chief Legal Officer	Sep 02 '25	Option Exercise	30.46	12,780	389,279	79,174	Sep 04 05:26 PM
Smith Michael Alexander	Chief Legal Officer	Sep 02 '25	Sale	143.89	24,272	3,492,378	54,902	Sep 04 05:26 PM
Flammer Martina M.D.	Chief Medical Officer	Sep 02 '25	Option Exercise	23.40	186,648	4,366,788	269,759	Sep 04 05:24 PM
Flammer Martina M.D.	Chief Medical Officer	Sep 02 '25	Sale	144.34	186,648	26,941,272	83,111	Sep 04 05:24 PM
Flammer Martina M.D.	Officer	Sep 02 '25	Proposed Sale	144.31	186,648	26,935,498		Sep 02 04:49 PM
Smith Michael Alexander	Officer	Sep 02 '25	Proposed Sale	143.85	24,272	3,491,647		Sep 02 04:41 PM
SHAROKY MELVIN MD	Director	Aug 20 '25	Sale	129.50	10,000	1,295,000	274,516	Aug 21 05:07 PM
Adsett Roger	Chief Operating Officer	Aug 19 '25	Sale	127.58	25,000	3,189,586	105,637	Aug 21 05:05 PM
Lewis William	Chair and CEO	Aug 18 '25	Option Exercise	10.85	6,865	74,485	240,789	Aug 20 04:28 PM
Lewis William	Chair and CEO	Aug 18 '25	Sale	128.40	6,865	881,470	233,924	Aug 20 04:28 PM
SHAROKY MELVIN MD	Director	Aug 20 '25	Proposed Sale	129.46	10,000	1,294,600		Aug 20 12:53 PM
Adsett Roger	Officer	Aug 19 '25	Proposed Sale	127.55	25,000	3,188,795		Aug 19 05:19 PM
Lewis William	Officer	Aug 18 '25	Proposed Sale	128.37	6,865	881,244		Aug 18 04:58 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Aug 14 '25	Sale	127.34	10,000	1,273,363	79,764	Aug 18 04:19 PM
SHAROKY MELVIN MD	Director	Aug 12 '25	Sale	121.58	10,000	1,215,800	290,616	Aug 14 04:21 PM
Schaeffer Orlov S Nicole	Officer	Aug 14 '25	Proposed Sale	127.31	10,000	1,273,070		Aug 14 04:10 PM
ALFRED ALTOMARI	Former Affiliate	Aug 13 '25	Proposed Sale	121.64	13,600	1,654,338		Aug 13 04:22 PM
SHAROKY MELVIN MD	Director	Aug 12 '25	Proposed Sale	121.53	10,000	1,215,350		Aug 12 04:37 PM
Lewis William	Chair and CEO	Aug 04 '25	Option Exercise	10.85	6,830	74,106	240,754	Aug 06 04:21 PM
Lewis William	Chair and CEO	Aug 04 '25	Sale	109.81	6,830	750,008	233,924	Aug 06 04:21 PM
Flammer Martina M.D.	Chief Medical Officer	Aug 04 '25	Option Exercise	19.74	8,715	172,034	91,826	Aug 06 04:19 PM
Flammer Martina M.D.	Chief Medical Officer	Aug 04 '25	Sale	109.50	8,715	954,292	83,111	Aug 06 04:19 PM
Lewis William	Officer	Aug 04 '25	Proposed Sale	109.78	6,830	749,801		Aug 04 04:37 PM
Flammer Martina M.D.	Officer	Aug 04 '25	Proposed Sale	109.47	8,715	954,031		Aug 04 04:24 PM
Bonstein Sara	Chief Financial Officer	Jul 21 '25	Option Exercise	30.63	47,888	1,466,711	131,905	Jul 23 04:35 PM
Bonstein Sara	Chief Financial Officer	Jul 21 '25	Sale	102.67	58,400	5,996,094	73,505	Jul 23 04:35 PM
Bonstein Sara	Officer	Jul 21 '25	Proposed Sale	102.64	58,400	5,994,443		Jul 21 04:13 PM
Lewis William	Chair and CEO	Jul 15 '25	Option Exercise	10.85	6,830	74,106	240,754	Jul 15 05:53 PM
Lewis William	Chair and CEO	Jul 15 '25	Sale	102.37	6,830	699,220	233,924	Jul 15 05:53 PM
Smith Michael Alexander	Chief Legal Officer	Jul 15 '25	Sale	102.51	933	95,642	66,394	Jul 15 05:52 PM
Smith Michael Alexander	Chief Legal Officer	Jul 11 '25	Sale	96.41	748	72,115	67,327	Jul 15 05:52 PM
Smith Michael Alexander	Officer	Jul 15 '25	Proposed Sale	102.48	933	95,617		Jul 15 04:27 PM
Lewis William	Officer	Jul 15 '25	Proposed Sale	102.35	6,830	699,036		Jul 15 04:21 PM
Smith Michael Alexander	Officer	Jul 11 '25	Proposed Sale	96.41	748	72,114		Jul 11 04:06 PM
Bonstein Sara	Chief Financial Officer	Jul 07 '25	Option Exercise	25.41	47,888	1,216,773	141,781	Jul 09 04:18 PM
Bonstein Sara	Chief Financial Officer	Jul 07 '25	Sale	95.86	57,764	5,537,460	84,017	Jul 09 04:18 PM
Bonstein Sara	Officer	Jul 07 '25	Proposed Sale	95.83	57,764	5,535,591		Jul 07 04:38 PM
Lewis William	Chair and CEO	Jul 01 '25	Option Exercise	10.85	6,830	74,106	240,754	Jul 02 04:06 PM
Lewis William	Chair and CEO	Jul 01 '25	Sale	98.33	6,830	671,612	233,924	Jul 02 04:06 PM
Lewis William	Officer	Jul 01 '25	Proposed Sale	98.30	6,830	671,409		Jul 01 04:47 PM
Bonstein Sara	Chief Financial Officer	Jun 23 '25	Option Exercise	19.16	47,889	917,479	151,301	Jun 25 04:18 PM
Bonstein Sara	Chief Financial Officer	Jun 23 '25	Sale	101.78	57,765	5,879,089	93,536	Jun 25 04:18 PM
Bonstein Sara	Officer	Jun 23 '25	Proposed Sale	101.75	57,765	5,877,434		Jun 23 04:11 PM
Wise John Drayton	Former Officer	Jun 23 '25	Proposed Sale	104.97	20,000	2,099,400		Jun 23 04:11 PM
Lewis William	Chair and CEO	Jun 16 '25	Option Exercise	10.85	129,805	1,408,384	363,729	Jun 18 04:16 PM
Lewis William	Chair and CEO	Jun 16 '25	Sale	100.39	129,805	13,031,681	233,924	Jun 18 04:16 PM
Lewis William	Chair and CEO	Jun 16 '25	Sale	100.32	5,204	522,063	303,554	Jun 18 04:16 PM
Adsett Roger	Chief Operating Officer	Jun 16 '25	Sale	98.82	10,686	1,056,004	130,637	Jun 18 04:15 PM
Lewis William	Officer	Jun 16 '25	Proposed Sale	100.36	135,009	13,549,587		Jun 16 05:01 PM
Adsett Roger	Officer	Jun 16 '25	Proposed Sale	98.79	10,686	1,055,688		Jun 16 04:08 PM
Wise John Drayton	Former Officer	Jun 13 '25	Proposed Sale	98.01	4,486	439,681		Jun 13 04:04 PM
Flammer Martina M.D.	Chief Medical Officer	Jun 10 '25	Option Exercise	26.46	25,740	681,080	108,851	Jun 12 04:21 PM
Flammer Martina M.D.	Chief Medical Officer	Jun 11 '25	Option Exercise	17.07	19,423	331,551	102,534	Jun 12 04:21 PM
Flammer Martina M.D.	Chief Medical Officer	Jun 10 '25	Sale	88.64	25,740	2,281,594	83,111	Jun 12 04:21 PM
Flammer Martina M.D.	Chief Medical Officer	Jun 11 '25	Sale	94.50	19,423	1,835,474	83,111	Jun 12 04:21 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Jun 11 '25	Option Exercise	13.91	70,000	973,700	188,579	Jun 12 04:20 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Jun 10 '25	Option Exercise	17.16	38,300	657,228	156,879	Jun 12 04:20 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Jun 11 '25	Sale	93.42	99,172	9,264,345	89,407	Jun 12 04:20 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Jun 10 '25	Sale	88.64	38,300	3,394,912	118,579	Jun 12 04:20 PM
Bonstein Sara	Chief Financial Officer	Jun 10 '25	Option Exercise	18.02	47,890	862,884	161,178	Jun 12 04:19 PM
Bonstein Sara	Chief Financial Officer	Jun 10 '25	Sale	89.12	57,766	5,148,024	103,412	Jun 12 04:19 PM
Flammer Martina M.D.	Officer	Jun 11 '25	Proposed Sale	94.47	19,423	1,834,890		Jun 11 04:41 PM
Schaeffer Orlov S Nicole	Officer	Jun 11 '25	Proposed Sale	93.39	99,172	9,261,326		Jun 11 04:19 PM
Bonstein Sara	Officer	Jun 10 '25	Proposed Sale	89.09	57,766	5,146,207		Jun 10 05:24 PM
Flammer Martina M.D.	Officer	Jun 10 '25	Proposed Sale	88.61	25,740	2,280,821		Jun 10 05:18 PM
Schaeffer Orlov S Nicole	Officer	Jun 10 '25	Proposed Sale	88.61	38,300	3,393,763		Jun 10 05:13 PM
ALFRED ALTOMARI	Director	Jun 10 '25	Proposed Sale	70.68	25,000	1,767,000		Jun 10 04:24 PM
Smith Michael Alexander	Chief Legal Officer	Jun 05 '25	Sale	73.50	1,879	138,106	67,718	Jun 06 04:53 PM
Smith Michael Alexander	Officer	Jun 05 '25	Proposed Sale	73.47	1,879	138,050		Jun 05 04:38 PM
Smith Michael Alexander	Chief Legal Officer	Jun 03 '25	Sale	71.50	1,448	103,532	69,597	Jun 04 05:38 PM
Flammer Martina M.D.	Chief Medical Officer	Jun 03 '25	Sale	71.50	1,686	120,549	83,111	Jun 04 05:37 PM
Adsett Roger	Chief Operating Officer	Jun 03 '25	Sale	71.50	1,860	132,990	141,323	Jun 04 05:36 PM
Bonstein Sara	Chief Financial Officer	Jun 03 '25	Sale	71.50	1,579	112,898	113,288	Jun 04 05:36 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Jun 03 '25	Sale	71.50	1,642	117,403	118,579	Jun 04 04:42 PM
MCGIRR DAVID W J	Director	Jun 03 '25	Sale	71.30	3,250	231,725	100,723	Jun 04 04:41 PM
MCGIRR DAVID W J	Director	Jun 04 '25	Sale	73.27	3,000	219,810	97,723	Jun 04 04:41 PM
Lewis William	Chair and CEO	Jun 02 '25	Option Exercise	10.85	6,830	74,106	240,754	Jun 04 04:40 PM
Lewis William	Chair and CEO	Jun 02 '25	Sale	71.31	6,830	487,044	233,924	Jun 04 04:40 PM
Lewis William	Chair and CEO	Jun 03 '25	Sale	71.50	5,472	391,248	308,758	Jun 04 04:40 PM
MCGIRR DAVID W J	Director	Jun 04 '25	Proposed Sale	73.27	3,000	219,804		Jun 04 12:33 PM
Bonstein Sara	Officer	Jun 03 '25	Proposed Sale	71.50	1,579	112,898		Jun 03 05:32 PM
Flammer Martina M.D.	Officer	Jun 03 '25	Proposed Sale	71.50	1,686	120,549		Jun 03 05:24 PM
Adsett Roger	Officer	Jun 03 '25	Proposed Sale	71.50	1,860	132,990		Jun 03 05:15 PM
Smith Michael Alexander	Officer	Jun 03 '25	Proposed Sale	71.50	1,448	103,532		Jun 03 05:09 PM
Wise John Drayton	Former Officer	Jun 03 '25	Proposed Sale	71.50	1,860	132,990		Jun 03 05:00 PM
Schaeffer Orlov S Nicole	Officer	Jun 03 '25	Proposed Sale	71.50	1,642	117,403		Jun 03 04:43 PM
Lewis William	Officer	Jun 03 '25	Proposed Sale	71.50	5,472	391,248		Jun 03 04:37 PM
Smith Michael Alexander	Chief Legal Officer	May 30 '25	Sale	69.65	26,327	1,833,779	71,045	Jun 03 04:02 PM
MCGIRR DAVID W J	Director	Jun 03 '25	Proposed Sale	71.30	3,250	231,725		Jun 03 12:50 PM
Lewis William	Officer	Jun 02 '25	Proposed Sale	71.28	6,830	486,834		Jun 02 04:35 PM
Smith Michael Alexander	Officer	May 30 '25	Proposed Sale	69.63	26,327	1,833,031		May 30 04:08 PM
Wise John Drayton	Former Officer	May 29 '25	Proposed Sale	66.60	6,691	445,620		May 29 04:22 PM
Wise John Drayton	Former Officer	May 28 '25	Proposed Sale	68.00	3,431	233,308		May 28 04:14 PM
Desjardins Clarissa	Director	May 20 '25	Buy	66.87	1,895	126,719	1,895	May 22 05:20 PM
Desjardins Clarissa	Director	May 21 '25	Buy	66.35	1,130	74,976	3,025	May 22 05:20 PM
Lewis William	Chair and CEO	May 20 '25	Option Exercise	10.85	6,830	74,106	240,754	May 22 05:18 PM
Lewis William	Chair and CEO	May 20 '25	Sale	67.65	21,057	1,424,447	314,230	May 22 05:18 PM
Lewis William	Chair and CEO	May 20 '25	Sale	67.72	6,830	462,510	233,924	May 22 05:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INSM

Insmed Inc

Upgrade your FINVIZ experience